Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy

BACKGROUND: Erdheim–Chester disease (ECD), a rare inflammatory myeloid neoplasm, is known to be fundamentally reliant on the constitutive activation of the MAPK signaling pathway in the majority of patients. Consequently, inhibition of the V600E-mutant BRAF kinase has proven to be a safe and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazor, Roei D, Weissman, Ran, Luckman, Judith, Domachevsky, Liran, Diamond, Eli L, Abdel-Wahab, Omar, Shapira, Shirley, Hershkovitz-Rokah, Oshrat, Groshar, David, Shpilberg, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212923/
https://www.ncbi.nlm.nih.gov/pubmed/32642685
http://dx.doi.org/10.1093/noajnl/vdaa024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212923/
https://www.ncbi.nlm.nih.gov/pubmed/32642685
http://dx.doi.org/10.1093/noajnl/vdaa024

Ejemplares similares